4156-75-6

Basic information

• Product Name: LACTONE 5-HYDROXYMETHYL OROTIC ACID
• Synonyms: LACTONE 5-HYDROXYMETHYL OROTIC ACID;furo[3,4-d]pyriMidine-2,4,7(1H,3H,5H)-trione;Furo[3,4-d]pyriMidine-2,4,7(3H)-trione, 1,5-dihydro-;1,5-dihydro-Furo[3,4-d]pyriMidine-2,4,7(3H)-trione;1,5-Dihydro-furo[3,4-d]pyrimidine-2,4,7-trione;1,5-dihydrofuro[4,3-e]pyrimidine-2,4,7-trione;1H,2H,3H,4H,5H,7H-Furo[3,4-d]pyrimidine-2,4,7-trione
• CAS NO: 4156-75-6
• Molecular Formula: C₆H₄N₂O₄
• Molecular Weight: 168.11
• Mol File: 4156-75-6.mol
• Article Data: 7

Chemical Properties

• Melting Point: 310-312 °C
• Appearance: /
• Density: 1.73 g/cm³
• Refractive Index: 1.631
• Storage Temp.: 2-8°C
• PKA: 7.96±0.20(Predicted)
• CAS DataBase Reference: LACTONE 5-HYDROXYMETHYL OROTIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: LACTONE 5-HYDROXYMETHYL OROTIC ACID(4156-75-6)
• EPA Substance Registry System: LACTONE 5-HYDROXYMETHYL OROTIC ACID(4156-75-6)

Safety Data

• Hazardous Substances Data: 4156-75-6(Hazardous Substances Data)

Usage

General Description

LACTONE 5-HYDROXYMETHYL OROTIC ACID, also known as 5-hydroxymethylorotic acid lactone, is a chemical compound with potential pharmaceutical applications. It is an important intermediate in the biosynthesis of pyrimidines, which are essential components of DNA and RNA. LACTONE 5-HYDROXYMETHYL OROTIC ACID is also involved in the production of uridine monophosphate (UMP), a key precursor in the synthesis of the nucleotide uridine, which is essential for protein and nucleic acid metabolism. Additionally, LACTONE 5-HYDROXYMETHYL OROTIC ACID has been studied for its potential therapeutic effects in conditions such as liver disease, as it has been shown to have hepatoprotective and anti-fibrotic properties in animal models. Its unique chemical structure and biological activities make it a promising target for further research and development in the field of medicine.

InChI:InChI=1/C6H4N2O4/c9-4-2-1-12-5(10)3(2)7-6(11)8-4/h1H2,(H2,7,8,9,11)

Upstream product

• 6341-93-1 orotic acid 
• 50-00-0 formaldehyd 
• 65-86-1 2,4-dihydroxypyrimidine-6-carboxylic acid 
• 65-86-1 orotic acid 

Downstream Products

• 15783-48-9 2,4-dichlorofuro[3,4-d]pyrimidin-7(5H)-one 
• 78202-89-8 6-carbamoyl-5-phenylthiomethyluracil 
• 78202-48-9 2,6-Dioxo-5-phenylaminomethyl-1,2,3,6-tetrahydro-pyrimidine-4-carboxylic acid amide 
• 78202-83-2 6-methoxycarbonyl-5-phenylthiomethyluracil 
• 78202-78-5 5-benzyloxymethyl-6-carbamoyluracil 
• 78202-91-2 5-benzylthiomethyl-6-carbamoyluracil 
• 78202-47-8 2,6-Dioxo-5-phenylaminomethyl-1,2,3,6-tetrahydro-pyrimidine-4-carboxylic acid ethyl ester 
• 78202-70-7 5-benzyloxymethyl-6-ethoxycarbonyluracil 
• 78202-85-4 5-benzylthiomethyl-6-ethoxycarbonyluracil 
• 78202-79-6 6-carbamoyl-5-(2-phenylethoxymethyl)uracil 
• 78202-71-8 6-ethoxycarbonyl-5-(2-phenylethoxymethyl)uracil 
• 78202-49-0 5-[(4-Chloro-phenylamino)-methyl]-2,6-dioxo-1,2,3,6-tetrahydro-pyrimidine-4-carboxylic acid ethyl ester 
• 89000-19-1 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)furo<3,4-d>pyrimidine-2,4,7(1H,3H,5H)-trione 
• 78202-90-1 6-carbamoyl-5-(4-chlorophenylthiomethyl)uracil 

Relevant articles and documents

Probing the Reactivity of 2,4-Dichlorofuro[3,4-d ]pyrimidin-7-one: A Versatile and Underexploited Scaffold to Generate Substituted or Fused Pyrimidine Derivatives

Herein, we describe the results of our investigation on the chemical reactivity and versatility of a poorly explored scaffold: 2,4-dichlorofuro[3,4-d ]pyrimidin-7-one (3). Highly functionalized pyrimidines can be obtained with a divergent approach by reacting the key intermediate 3 with different amine nucleophiles under carefully controlled reaction conditions. The set-up of a microwave-Assisted one-pot, two-or three-step protocol to rapidly generate 2,4,5,6-Tetrasubstituted or fused pyrimidines is also reported.

Discovery of P2X3 selective antagonists for the treatment of chronic pain

Purinergic receptor P2X3 has been linked to analgesia in a number of pre-clinical models of pain, and is expressed in the human pain perception pathway. Only few P2X3-selective antagonists have been reported to date. This Letter describes the SAR and in vivo analgesic profile of a novel scaffold of selective P2X3 antagonists.

DIHYROFUROPYRMINDINE COMPOUNDS

The present invention provides mTOR inhibitors of the formula wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods of making the compounds and intermediates thereof; and methods of using the compounds.